Importer of Controlled Substances; Notice of Application; Myoderm, 39741 [2012-16493]

Download as PDF Federal Register / Vol. 77, No. 129 / Thursday, July 5, 2012 / Notices Order determining any adjustment of the aggregate production quota. Dated: June 28, 2012. Michele M. Leonhart, Administrator. [FR Doc. 2012–16396 Filed 7–3–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application; Myoderm Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on May 9, 2012, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401, made application to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances: Drug Schedule TKELLEY on DSK3SPTVN1PROD with NOTICES Amphetamine (1100) .................... Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Pentobarbital (2270) ..................... Nabilone (7379) ............................ Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Levomethorphan (9210) ............... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Oxymorphone (9652) ................... Fentanyl (9801) ............................ II II II II II II II II II II II II II II II II Dated: June 28, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–16493 Filed 7–3–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE National Institute of Corrections The company plans to import the listed controlled substances in finished dosage form for clinical trials, and research. The import of the above listed basic classes of controlled substances would be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or nonapproved dosage form for commercial distribution in the United States. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant VerDate Mar<15>2010 16:48 Jul 03, 2012 Jkt 226001 to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 6, 2012. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Solicitation for a Cooperative Agreement—Curricula Review and Revision: NIC Trainer Development Series National Institute of Corrections, U.S. Department of Justice. ACTION: Solicitation for a Cooperative Agreement. AGENCY: The National Institute of Corrections’ (NIC) Academy Division is soliciting proposals from organizations, groups, or individuals to enter into a cooperative agreement for the review, revision, and/or development of competency-based, blended modality training curricula with the aim of providing corrections agencies and professionals with the knowledge, skills, and abilities needed to train and develop their staff. DATES: Application must be received by 4 p.m. (EDT) on Friday, July 20, 2012. ADDRESSES: Mailed applications must be sent to: Director, National Institute of Corrections, 320 First Street NW., Room 5002, Washington, DC 20534. SUMMARY: PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 39741 Applicants are encouraged to use Federal Express, UPS, or similar service to ensure delivery by the due date. Hand delivered applications should be brought to 500 First Street NW., Washington, DC 20534. At the front desk, dial 7–3106, extension 0 for pickup. Faxed applications will not be accepted. Electronic applications can be submitted via https://www.grants.gov. FOR FURTHER INFORMATION CONTACT: All technical or programmatic questions concerning this announcement should be directed to Michael Guevara, Correctional Program Specialist, National Institute of Corrections. Mr. Guevara can be reached by calling 800– 995–6429, ext. 6617, or by email at mguevar@bop.gov. In addition to the direct reply, all questions and responses will be posted on NIC’s Web site at www.nicic.gov for public review (the names of those submitting questions will not be posted). The Web site will be updated regularly and postings will remain on the Web site until the closing date of this cooperative agreement solicitation. Only questions received by 12 p.m. (EDT) on July 13, 2012 will be posted on the NIC Web site. SUPPLEMENTARY INFORMATION: Overview: NIC is revitalizing its trainer development series with the goal of helping corrections agencies and trainers improve staff training and development. NIC is interested in updating some of its curricula, including ‘‘Training Design and Development,’’ ‘‘Foundation Skills for Trainers,’’ ‘‘Building Agency Success: Developing an Effective FTO/OJT Training Program,’’ and ‘‘Training for Training Directors.’’ NIC is also interested in the development of a model Training for Trainers template that could be applied broadly, enabling agencies to train trainers in existing curricula. All curricula will follow the Instructional Theory into Practice (ITIP) model and will incorporate blended learning strategies. A copy of the ‘‘ITIP Toolkit,’’ which may be useful in helping awardees develop acceptable curricula, is available on the NIC Web site at https://nicic.gov/Library/024773. An essential component of this project will be the incorporation of current research on adult learning and performance. The use of multiple delivery technologies is required. Background: NIC has prioritized capacity building in corrections agencies for decades. While NIC frequently relied on traditional classroom-based training in the past, the emergence of new technologies and the E:\FR\FM\05JYN1.SGM 05JYN1

Agencies

[Federal Register Volume 77, Number 129 (Thursday, July 5, 2012)]
[Notices]
[Page 39741]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-16493]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; Myoderm

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on May 9, 2012, Myoderm, 48 East Main Street, 
Norristown, Pennsylvania 19401, made application to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................   II
Hydromorphone (9150).......................   II
Hydrocodone (9193).........................   II
Levomethorphan (9210)......................   II
Meperidine (9230)..........................   II
Methadone (9250)...........................   II
Methadone intermediate (9254)..............   II
Morphine (9300)............................   II
Oxymorphone (9652).........................   II
Fentanyl (9801)............................   II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances in 
finished dosage form for clinical trials, and research.
    The import of the above listed basic classes of controlled 
substances would be granted only for analytical testing and clinical 
trials. This authorization does not extend to the import of a finished 
FDA approved or non-approved dosage form for commercial distribution in 
the United States.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedule I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 6, 2012.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: June 28, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-16493 Filed 7-3-12; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.